Verseon (LSE:VERS) Change In Receivables : £0.00 Mil (TTM As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Change In Receivables?

Verseon's change in receivables for the quarter that ended in Jun. 2019 was £0.00 Mil. It means Verseon's Accounts Receivable stayed the same from Dec. 2018 to Jun. 2019 .

Verseon's change in receivables for the fiscal year that ended in Dec. 2018 was £0.00 Mil. It means Verseon's Accounts Receivable stayed the same from Dec. 2017 to Dec. 2018 .

Verseon's Accounts Receivable for the quarter that ended in Jun. 2019 was £0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Verseon's liquidation value for the six months ended in Jun. 2019 was £-24.76 Mil.

Verseon Change In Receivables Historical Data

The historical data trend for Verseon's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Change In Receivables Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Change In Receivables

Get a 7-Day Free Trial

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Change In Receivables	Get a 7-Day Free Trial									-	-	-	-	-

Verseon Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2019 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Verseon (LSE:VERS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Verseon's Days Sales Outstanding for the quarter that ended in Jun. 2019 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Verseon's accounts receivable are only considered to be worth 75% of book value:

Verseon's liquidation value for the quarter that ended in Jun. 2019 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.786	-	26.542	+	0.75 * 0	+	0.5 * 0
=	-24.76

Verseon Change In Receivables Related Terms

Thank you for viewing the detailed overview of Verseon's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.